These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 11996809

  • 1. Role of sphingosine synthesis inhibition in transcutaneous delivery of levodopa.
    Gupta BS, Tiwary AK.
    Int J Pharm; 2002 May 15; 238(1-2):43-50. PubMed ID: 11996809
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of skin sphingosine synthesis: enhanced percutaneous permeation of 5-fluorouracil.
    Gupta M, Mahajan A, Babita, Gupta S, Tiwary AK.
    Pharmazie; 2004 Mar 15; 59(3):212-6. PubMed ID: 15074596
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.
    Clin Pharmacol Ther; 1997 Sep 15; 62(3):300-10. PubMed ID: 9333106
    [Abstract] [Full Text] [Related]

  • 9. Transdermal absorption of L-dopa from hydrogel in rats.
    Sudo J, Iwase H, Terui J, Kakuno K, Soyama M, Takayama K, Nagai T.
    Eur J Pharm Sci; 1998 Dec 15; 7(1):67-71. PubMed ID: 9845779
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
    Hsu A, Yao HM, Gupta S, Modi NB.
    J Clin Pharmacol; 2015 Sep 15; 55(9):995-1003. PubMed ID: 25855267
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.
    Sintov AC, Levy HV, Greenberg I.
    Pharm Res; 2017 Jul 15; 34(7):1459-1468. PubMed ID: 28405912
    [Abstract] [Full Text] [Related]

  • 16. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M, Lopane G, Passini A, Poli F, Iannello C, Guarino M.
    Clin Neuropharmacol; 2015 Jul 15; 38(5):201-3. PubMed ID: 26366963
    [Abstract] [Full Text] [Related]

  • 17. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T, Ander L, Kolf K, Woitalla D, Muhlack S.
    J Neural Transm (Vienna); 2007 Jul 15; 114(11):1457-62. PubMed ID: 17564755
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits.
    Fernandez N, Prieto C, Sierra M, Diez MJ, Sahagun A, Gonzalez A, Garcia JJ.
    Methods Find Exp Clin Pharmacol; 2008 Jul 15; 30(6):451-7. PubMed ID: 18850046
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.